[
    [
        {
            "time": "",
            "original_text": "健帆生物一季度净利预增三至五成",
            "features": {
                "keywords": [
                    "健帆生物",
                    "一季度",
                    "净利",
                    "预增",
                    "三至五成"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物一季度净利预增三至五成",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "健帆生物(300529.SZ)：一季度净利预增30%-50%",
            "features": {
                "keywords": [
                    "健帆生物",
                    "300529.SZ",
                    "一季度",
                    "净利",
                    "预增",
                    "30%-50%"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物(300529.SZ)：一季度净利预增30%-50%",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "健帆生物：预计一季度盈利1.68亿-1.94亿元，同比增长30%-50%",
            "features": {
                "keywords": [
                    "健帆生物",
                    "一季度",
                    "盈利",
                    "1.68亿-1.94亿元",
                    "同比增长",
                    "30%-50%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物：预计一季度盈利1.68亿-1.94亿元，同比增长30%-50%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "【东北医药崔洁铭】健帆生物（300529）年报点评：业绩稳定高增长，肝肾病产品空间巨大",
            "features": {
                "keywords": [
                    "东北医药",
                    "崔洁铭",
                    "健帆生物",
                    "300529",
                    "年报",
                    "业绩",
                    "稳定高增长",
                    "肝肾病",
                    "产品",
                    "空间巨大"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【东北医药崔洁铭】健帆生物（300529）年报点评：业绩稳定高增长，肝肾病产品空间巨大",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]